



April 25, 2023

[AGO.highcostprescriptiondrugs@vermont.gov](mailto:AGO.highcostprescriptiondrugs@vermont.gov)

Report Concerning a New Prescription Drug Pursuant to 18 V.S.A. § 4637(c)

Dear Office of the Vermont Attorney General,

Par Pharmaceutical, Inc. (“Par”) is issuing this notice pursuant to 18 V.S.A. § 4637(c), which asks prescription drug manufacturers to report certain information to the Office of the Attorney General (the “Office”) within thirty calendar days of providing initial notice to the Office that the manufacturer has released a drug in the commercial market whose wholesale acquisition cost (“WAC”) exceeds the threshold set for a specialty drug under the Medicare Part D Program.

On March 27, 2023, Par informed the Office that it introduced Everolimus Tablets into the commercial market at a WAC per course of therapy that exceeds the threshold set for a specialty drug under the Medicare Part D Program.

Below is the information related to Everolimus Tablets, issued pursuant to 18 V.S.A. § 4637(c). Consistent with 18 V.S.A. § 4637(d), Par has limited the below information to what Par believes is otherwise in the public domain or publicly available.

<b>18 V.S.A. § 4637(c) Reporting Requirement</b>	<b>Response for Everolimus Tablets</b>
Description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally	Par does not believe this information is otherwise in the public domain or publicly available. Accordingly, Par is limiting its response to this item pursuant to 18 V.S.A. § 4637(d).
Estimated volume of patients who may be prescribed the drug	Par has not been able to identify an estimate of the total number of patients in the U.S. who may be prescribed this product through publicly available resources. Accordingly, Par is limiting its response to this item pursuant to 18 V.S.A. § 4637(d).

<b>18 V.S.A. § 4637(c) Reporting Requirement</b>	<b>Response for Everolimus Tablets</b>
Whether the drug was granted breakthrough therapy designation by the federal Food and Drug Administration prior to final approval	No.
Whether the drug was granted priority review by the federal Food and Drug Administration prior to final approval	No.
The date and price of acquisition if the drug was not developed by the manufacturer	Not applicable. Par did not acquire this product from another manufacturer.

In the event 18 V.S.A. § 4637 is found invalid, Par reserves all of its legal rights. In issuing this notice in an attempt to comply with 18 V.S.A. § 4637, Par does not waive any legal claims or legal rights related to potential constitutional defects with 18 V.S.A. § 4637.

Sincerely,

*Gregory Halen*

Gregory Halen,  
Senior Manager, Government Contracts and Pricing